FILSPARI

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Italy, Lithuania.

Active ingredients

The drug FILSPARI contains one active pharmaceutical ingredient (API):

1	Sparsentan UNII 9242RO5URM - SPARSENTAN
	Sparsentan is a dual endothelin angiotensin receptor antagonist. It is a single molecule that functions as a high affinity, dual-acting antagonist of both the ETAR and AT1R. Endothelin 1, via ETAR, and angiotensin II, via AT1R, mediate processes that lead to IgAN progression through haemodynamic actions and mesangial cell proliferation, increased expression and activity of proinflammatory and profibrotic mediators, podocyte injury, and oxidative stress. Sparsentan inhibits activation of both ETAR and AT1R and thereby reduces proteinuria and slows the progression of kidney disease.
	Read more about Sparsentan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FILSPARI Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
FILSPARI Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09XX01		C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09X Other agents acting on the renin-angiotensin system → C09XX Other agents acting on the renin-angiotensin system
Discover more medicines within C09XX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3083925, 3083936, 3084140
FR	Base de données publique des médicaments	63617869, 68110738
IT	Agenzia del Farmaco	051214017, 051214029
LT	Valstybinė vaistų kontrolės tarnyba	1099663, 1099664
US	FDA, National Drug Code	68974-200, 68974-400